Kringle Pharma, Inc. (4884) Press Release
Kringle Pharma Announces IND Submission to the U.S. FDA for Oremepermin Alfa for the Treatment of Acute Spinal Cord Injury
Filed with TSE ·
6ix hasn’t read this filing yet.
Earlier from Kringle Pharma
- Financial Results for the Nine Months Ended June 30, 2026 [Japanese GAAP] (Non-consolidated)
- Kringle Pharma Advances the Registrational Program for Oremepermin Alfa in Japan with Initiation of Additional Phase 3 in Acute Spinal Cord Injury
- Kringle Pharma: Update on the Investigator-initiated Phase 2 Study in Patients with ALS
- Kringle Pharma: Files Patent Application for Treatment of Chronic Spinal Cord Injury